Home > News > Headline News > Archive

Click on title to read the full article.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 14, 2014

By Onc Live: Christina Izzo

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists. To provide further perspective on current paradigms, OncLive interviewed Debu Tripathy, MD, a breast cancer expert whose clinical research efforts focus on novel therapeutics, resistance, and the discovery of biomarkers.

Tripathy, a professor of medicine and the co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, serves as the primary investigator for the Systematic Therapies for HER2-positive Metastatic Brest Cancer Study (SystHERs), which hopes to provide information on treatment patterns across the United States.

Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive

August 12, 2014

By Merrimack Pharmaceuticals press release

Trial is Recruiting Patients Previously Treated With Ado-Trastuzumab Emtansine (T-DM1) and Pertuzumab

CAMBRIDGE, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the initiation of a global, open-label, randomized Phase 2 trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin®) in patients with HER2-positive locally advanced or metastatic breast cancer. The trial was designed with input from the U.S. Food and Drug Administration (FDA) to support a potential accelerated approval application.

"While there have been new therapies approved in the HER2-positive setting, there is no standard of care for patients whose cancer progresses despite treatment with trastuzumab, T-DM1 and pertuzumab. In our experience to date, MM-302 has shown promising clinical activity and an acceptable safety profile in patients with metastatic breast cancer who have progressed on HER2-directed therapies. We are moving this trial forward with a goal of transforming the standard of care for this population," said Thomas Wickham, Ph.D., Vice President of Development and MM-302 Project Team Leader.